Monoclonal antibody exposure in rat and cynomolgus monkey cerebrospinal fluid following systemic administration-Reference-Cited by-同舟云学术

Monoclonal antibody exposure in rat and cynomolgus monkey cerebrospinal fluid following systemic administration

Published:2018-03-20 Issue:1 Volume:15 Page:
ISSN:2045-8118
Container-title:Fluids and Barriers of the CNS
language:en
Short-container-title:Fluids Barriers CNS

Author:

Wang Qin^ORCID,Delva Luisette,Weinreb Paul H.,Pepinsky Robert B.,Graham Danielle,Veizaj Elvana,Cheung Anne E.,Chen Weiping,Nestorov Ivan,Rohde Ellen,Caputo Robin,Kuesters Geoffrey M.,Bohnert Tonika,Gan Liang-Shang

Funder

The studies were sponsored by Biogen. All authors and Biogen have approved the manuscript and this submission.

Publisher

Springer Science and Business Media LLC

Subject

Cellular and Molecular Neuroscience,Developmental Neuroscience,Neurology,General Medicine

Link

http://link.springer.com/content/pdf/10.1186/s12987-018-0093-6.pdf

Reference49 articles.

1. Hammarlund-Udenaes M, et al. On the rate and extent of drug delivery to the brain. Pharm Res. 2008;25(8):1737–50.

2. Lin JH. CSF as a surrogate for assessing CNS exposure: an industrial perspective. Curr Drug Metab. 2008;9(1):46–59.

3. Liu X, et al. Unbound drug concentration in brain homogenate and cerebral spinal fluid at steady state as a surrogate for unbound concentration in brain interstitial fluid. Drug Metab Dispos. 2009;37(4):787–93.

4. Badhan RK, Chenel M, Penny JI. Development of a physiologically-based pharmacokinetic model of the rat central nervous system. Pharmaceutics. 2014;6(1):97–136.

5. de Lange EC. Utility of CSF in translational neuroscience. J Pharmacokinet Pharmacodyn. 2013;40(3):315–26.

Cited by 47 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Alzheimer’s disease and immunotherapy;Current Medicine;2024-08-23

2. An anti-sortilin affibody-peptide fusion inhibits sortilin-mediated progranulin degradation;Frontiers in Immunology;2024-08-08

3. Exploring How Antibody Format Drives Clearance from the Brain;Molecular Pharmaceutics;2024-07-26

4. Innovative Formulation Platform: Paving the Way for Superior Protein Therapeutics with Enhanced Efficacy and Broadened Applications;Advanced Materials;2024-06-16

5. Investigation of Antibody Pharmacokinetics in the Brain Following Intra-CNS Administration and Development of PBPK Model to Characterize the Data;The AAPS Journal;2024-03-05